Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
The role of statin therapy in chronic kidney disease (CKD) remains controversial, with conflicting evidence regarding renal protection and cardiovascular benefits. This umbrella review synthesizes evidence from four recent meta-analyses to clarify these effects.
This umbrella review synthesized systematic reviews and meta-analyses of randomized controlled trials published from inception to August 2025. PubMed, EMBASE, and Cochrane Library were searched for meta-analyses examining statin therapy in adults with chronic kidney disease. Primary outcomes included kidney failure events, estimated glomerular filtration rate (eGFR) decline, proteinuria changes, and major cardiovascular events. Methodological quality was assessed using AMSTAR 2, and area under the curve analysis was conducted. Statistical measures included odds ratios (OR), relative risk (RR), mean differences (MD), standardized mean differences (SMD), and weighted mean differences (WMD), all reported with 95% confidence intervals (CI).
Cardiovascular Outcomes: Su et al. (2016), analyzing 57 randomized controlled trials, found statins significantly reduced cardiovascular events (OR 0.69; 95% CI 0.61–0.79). Palmer et al. (2012), reviewing 31 trials, reported statins lowered major cardiovascular events by 23% (RR 0.77; 95% CI 0.70–0.84), coronary events by 18% (RR 0.82; 95% CI 0.73–0.92), and all-cause or cardiovascular mortality by 9% (RR 0.91; 95% CI 0.84–0.99).
Renal Outcomes: For kidney function, Su et al. demonstrated statin therapy was associated with slower eGFR decline (MD 0.41; 95% CI 0.11–0.70) and reduced proteinuria (SMD −0.65; 95% CI −0.94 to −0.37), though no effect on kidney failure events (OR 0.98; 95% CI 0.87–1.10). Hou et al. (2013), based on 20 trials, showed statins reduced urinary protein excretion (−0.77 g/24h; 95% CI −1.24 to −0.29) and improved eGFR over 1–3 years (MD 0.50 mL/min/1.73m²; 95% CI 0.40–0.60). Zhao et al. (2021), synthesizing 33 RCTs, found statins reduced urinary albumin (WMD −2.04; 95% CI −3.53 to −0.56) and protein (WMD −0.58; 95% CI −0.95 to −0.21), and increased creatinine clearance (WMD 0.86; 95% CI 0.32–1.41), but did not significantly change eGFR (WMD 0.38; 95% CI −0.04 to 0.79). Palmer et al. observed no benefit for kidney failure prevention (RR 0.95; 95% CI 0.89–1.10).
Statins provide consistent cardiovascular benefits and modest renoprotective effects in CKD patients, including reduced proteinuria and slowed eGFR decline, particularly with longer therapy. Evidence for kidney failure prevention remains inconclusive. These findings support statin therapy in CKD patients primarily for cardiovascular risk reduction, with additional potential renal benefits warranting consideration in clinical decision-making.
